{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:02:25Z","timestamp":1705276945207},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.vaccine.2004.08.022","type":"journal-article","created":{"date-parts":[[2004,9,21]],"date-time":"2004-09-21T18:24:21Z","timestamp":1095791061000},"page":"1061-1071","source":"Crossref","is-referenced-by-count":22,"title":["Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis"],"prefix":"10.1016","volume":"23","author":[{"given":"Bernadete Pereira da","family":"Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana Baptista Rocha Correa","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edilma Paraguai de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Palatnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisa Beatriz Palatnik de","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Paz","family":"Parente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.08.022_bib1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1359-6446(03)02864-2","article-title":"Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity","volume":"8","author":"Marciani","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.vaccine.2004.08.022_bib2","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1248\/cpb.41.2132","article-title":"Studies on the constituents of Calliandra anomala (Kunth) Macbr. I. Structure elucidation of two acylated triterpenoidal saponins","volume":"41","author":"Takeda","year":"1993","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.vaccine.2004.08.022_bib3","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1248\/cpb.44.816","article-title":"Studies on the constituents of Calliandra anomala (Kunth) Macbr. III. Structure elucidation of six acylated triterpenoidal saponins","volume":"44","author":"Tani","year":"1996","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.vaccine.2004.08.022_bib4","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1248\/cpb.46.723","article-title":"Studies on the constituents of Calliandra anomala (Kunth) Macbr. IV. Structure analysis by HPLC retention time and FAB-MS spectrum","volume":"46","author":"Tani","year":"1998","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.vaccine.2004.08.022_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1248\/cpb.42.1111","article-title":"Studies on the constituents of Calliandra anomala (Kunth) Macbr. II. Structure elucidation of four acylated triterpenoidal saponins","volume":"42","author":"Nakamura","year":"1994","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.vaccine.2004.08.022_bib6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/0031-9422(88)80295-4","article-title":"An acylated triterpenoid saponin from Quillaja saponaria","volume":"27","author":"Higuchi","year":"1988","journal-title":"Phytochemistry"},{"key":"10.1016\/j.vaccine.2004.08.022_bib7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0264-410X(94)80052-2","article-title":"Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma","volume":"12","author":"Livingston","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1089\/aid.1997.13.1163","article-title":"Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group","volume":"13","author":"Keefer","year":"1997","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2004.08.022_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria: RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2004.08.022_bib10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2460\/javma.1991.199.10.1423","article-title":"Development of a genetically engineered vaccine against feline leukemia virus infection","volume":"199","author":"Kensil","year":"1991","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2004.08.022_bib11","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/S0264-410X(00)00118-3","article-title":"Development of semi-synthetic triterpenoid saponin derivatives with immune stimulating activity","volume":"18","author":"Marciani","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib12","series-title":"Index y Sinonoma de las Plantas Medicinales de Mexico","year":"1976"},{"key":"10.1016\/j.vaccine.2004.08.022_bib13","series-title":"Plantas Ornamentais no Brasil: Arbustivas, Herb\u00e1ceas e Trepadeiras","year":"1995"},{"key":"10.1016\/j.vaccine.2004.08.022_bib14","series-title":"Plants for Malaria, Plants for Fever. Medicinal Species in Latin America \u2013 a Bibliographic Study","year":"1997"},{"key":"10.1016\/j.vaccine.2004.08.022_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL 12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-6215(95)00278-2","article-title":"Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy","volume":"280","author":"Jacobsen","year":"1996","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2004.08.022_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1042\/bj1510491","article-title":"Characterization by gas\u2013liquid chromatography-mass spectrometry and proton-magnetic-resonance spectroscopy of pertrimethylsilyl glycosides obtained in methanolysis of glycoproteins and glycopeptides","volume":"151","author":"Kamerling","year":"1975","journal-title":"Biochem J"},{"key":"10.1016\/j.vaccine.2004.08.022_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0008-6215(00)80881-2","article-title":"Determination of the D and L configuration of neutral monosaccharides by high-resolution capillary G.L.C.","volume":"62","author":"Gerwig","year":"1978","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2004.08.022_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0008-6215(00)90753-5","article-title":"A convenient method for methylation of glycoprotein glycans in small amounts by using lithium methylsulfinyl carbanion","volume":"141","author":"Parente","year":"1985","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2004.08.022_bib20","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1021\/ac60231a048","article-title":"Quantitative determination of monosaccharides as their alditol acetates by gas liquid chromatography","volume":"37","author":"Sawardeker","year":"1965","journal-title":"Anal Chem"},{"key":"10.1016\/j.vaccine.2004.08.022_bib21","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0264-410X(96)00292-7","article-title":"Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani","volume":"15","author":"Santos","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/IAI.57.3.754-763.1989","article-title":"Inhibition of Leishmania donovani internalization into murine macrophages by chemically-defined parasite glycoconjugate ligands","volume":"57","author":"Palatnik","year":"1989","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2004.08.022_bib23","first-page":"547","article-title":"Experimental murine Leishmania donovani infection immunoprotection by the Fucose Mannose Ligand (FML)","volume":"27","author":"Palatnik de Sousa","year":"1994","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.vaccine.2004.08.022_bib24","first-page":"290","article-title":"The FML vaccine (fucose\u2013mannose ligand) protects hamsters from experimental Kala-Azar","volume":"46","author":"Palatnik de Sousa","year":"1994","journal-title":"J Braz Assoc Adv Sci"},{"key":"10.1016\/j.vaccine.2004.08.022_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0031-9422(81)85233-8","article-title":"The structure of prosapogenin obtained from the saponin of Gleditsia japonica","volume":"20","author":"Konoshima","year":"1981","journal-title":"Phytochemistry"},{"key":"10.1016\/j.vaccine.2004.08.022_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2008-1074957","article-title":"Gleditsia Saponins I. Structures of Monoterpene Moieties of Gleditsia Saponin C","volume":"40","author":"Okada","year":"1980","journal-title":"Planta Med"},{"key":"10.1016\/j.vaccine.2004.08.022_bib27","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/S0264-410X(00)00415-1","article-title":"QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans","volume":"19","author":"Evans","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-2006-958006","article-title":"Haemolytic time course differences between steroid and triterpenoid saponins","volume":"61","author":"Takechi","year":"1995","journal-title":"Planta Med"},{"key":"10.1016\/j.vaccine.2004.08.022_bib29","unstructured":"Santos WR. Effect of the FML-vaccine on the cutaneous leishmaniasis and murine experimental kala-azar, Comparative analysis of adjuvants. Doctoral Thesis, Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil 2002."},{"key":"10.1016\/j.vaccine.2004.08.022_bib30","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/S0264-410X(01)00142-6","article-title":"Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21","volume":"19","author":"Waite","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1515\/BC.2000.009","article-title":"Adjuvant and haemolytic activities of 47 saponins derived from medicinal and food plants","volume":"381","author":"Oda","year":"2000","journal-title":"Biol Chem"},{"key":"10.1016\/j.vaccine.2004.08.022_bib32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4049\/jimmunol.146.2.431","article-title":"Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex","volume":"146","author":"Kensil","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2004.08.022_bib33","first-page":"1068","article-title":"A Phase III trial of Efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante RN)","volume":"19","author":"da Silva","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib34","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib35","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/S0264-410X(03)00046-X","article-title":"IgG1\/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis","volume":"21","author":"Mendes","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib36","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective Immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.022_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2249.2002.02016.x","article-title":"Discovery of immunopotentiatory drugs: current and future strategies","volume":"130","author":"Rhodes","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2004.08.022_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4269\/ajtmh.1992.46.123","article-title":"Leishmania chagasi antigens recognized in cured visceral leishmaniasis and asymptomatic infection","volume":"46","author":"White","year":"1992","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2004.08.022_bib39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1172\/JCI113969","article-title":"Antigen-specific immunosupression in visceral leishmaniasis is cell mediated","volume":"83","author":"Carvalho","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2004.08.022_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/IAI.62.1.229-235.1994","article-title":"Cellular and humoral immune responses in dogs experimentally and naturally infectes with Leishmania (L.) infantum","volume":"62","author":"Pinelli","year":"1994","journal-title":"Inf Immunol"},{"key":"10.1016\/j.vaccine.2004.08.022_bib41","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-3024.1992.tb00026.x","article-title":"Demostration of Leishmania specific cell mediated and humoral immunity in asymptomatic dogs","volume":"14","author":"Cabral","year":"1992","journal-title":"Parasite. Immunol"},{"key":"10.1016\/j.vaccine.2004.08.022_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-4017(00)00223-5","article-title":"The Ibizian hound presents a predominanttly cellular immune response against natural Leishmania infection","author":"Solano-Gallego","year":"2000","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2004.08.022_bib43","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/eji.1830220813","article-title":"Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell-mediated down-regulation of delayed-type hypersensitivity response and up-regulation of B cell activation","volume":"22","author":"Basak","year":"1992","journal-title":"Eur J Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04006309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04006309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T11:27:50Z","timestamp":1705231670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04006309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0264410X04006309"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.08.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}